GSK, Genmab ink deal to develop, commercialize ofatumumab
LONDON British drug maker GlaxoSmithKline has inked a co-development and commercialization agreement with Genmab, the drug makers said Thursday.
Under the terms of the agreement, GSK will take responsibility for developing ofatumumab, an investigational treatment for autoimmune diseases, whilst continuing to jointly develop ofatumumab with Genmab in oncology indications. Genmab will receive an upfront payment of GBP 90 million from GSK.
“Autoimmune diseases represent an area of high unmet medical need. GSK’s growing biopharmaceutical capabilities, coupled with our deep therapy-area expertise, will greatly facilitate the development of ofatumumab in these indications,” said Ian Tomlinson, SVP biopharmaceutical research and development at GSK.
Added Genmab CEO Jan G.J. van de Winkel, “The amendment to the ofatumumab agreement clearly highlights Genmab and GSK’s commitment to further develop this important product. We have a really excellent partner in GSK. Their flexibility has allowed us to not only ensure that we extract the best possible value from ofatumumab, but also strengthen the financial security of Genmab.”
Pampers by Cynthia Rowley hitting Target shelves in July
CINCINNATI Pampers has teamed up with renowned fashion designer Cynthia Rowley to bring fashionable diapers to Target shoppers this summer.
Pampers by Cynthia Rowley will be available in 11 colorful styles — for boys and girls — beginning in mid July at Target stores and on Target.com. Pampers by Cynthia Rowley incorporate a beautiful look and feel — giving discerning parents high performance, value and choice of style. The diaper collection, which will be available in pastel designs, including madras, stripes and printed ruffles, is suited specifically to babies and toddlers and delivers the perfect blend of utility and aesthetics.
“Of course parents want the very best for their little ones,” said Jodi Allen, Procter & Gamble’s VP North America baby care. “We also know that sometimes it’s the little things — like how a baby is clothed — that can bring added joy to mom and dad. While performance always comes first, we know that design is also important to parents. We’re pleased to introduce the first diaper line that brings together the best of these two worlds.”
Eisai, SuperGen release data for Dacogen trial
DUBLIN, Calif. Japanese drug maker Eisai has released data on a late-stage clinical trial of a drug for leukemia, Eisai’s development partner said Wednesday.
SuperGen said that while the injectable drug Dacogen (decitabine) did not show statistically significant superiority in overall survival in elderly patients with acute myeloid leukemia compared over treatments given to patients in the control group, “a trend was evident.”
Based on findings, Eisai plans to submit a regulatory application to the Food and Drug Administration seeking approval for Dacogen as a treatment for elderly patients with AML. The drug already is approved to treat myelodysplastic syndromes.